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Abstract: The Rab27 family of small GTPases regulates exocytosis of distinct vesicle 
types including multivesicular endosomes, which results in the release of exosomes. 
Exosomes are nanometer-sized membrane vesicles that enclose soluble factors such as 
proteins and nucleic acids within a lipid bilayer and can travel toward distant tissues to 
influence multiple aspects of cell behavior. In our view that tumors are endocrine organs 
producing exosomes, Rab27 GTPases and their effector proteins are critical determinants 
for invasive growth and metastasis. Rab27 proteins and their effectors may serve as 
prognostic biomarkers or as targets for patient-tailored therapy. 
Keywords: Rab GTPase; exosome; cancer; extracellular vesicle  
 
1. Introduction 
Tumors are ecosystems characterized by an intense communication between cancer cells and 
stromal cells [1]. These heterotypic interactions are a prerequisite for invasive growth and the final 
stage of multi-step tumor progression—metastasis [2]. Secretory products from both cancer cells and 
stromal cells are part of an endocrine signaling network that initiates the formation of a metastatic 
niche, a landing dock for future metastatic colonization [3]. Subpopulations of cancer stem cells 
educate target organs to resemble the primary tumor environment and recruit precursor cells from 
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reservoir sites such as bone marrow [4]. Desmoplasia consisting of carcinoma-associated fibroblasts 
and extracellular matrix deposition is a morphological evidence of stroma participation in the primary 
tumor and metastatic niches [5]. 
Communication in the tumor ecosystem involves direct cell-cell interactions, but also the release of 
single molecules (growth factors, cytokines, chemokines, proteases, matrix molecules) and membrane 
vesicles that enclose soluble factors within a lipid bilayer [6]. An example of single molecule 
communication is the recruitment of mesenchymal stem cells from the bone marrow reservoir to the 
primary tumor and the release of neuregulin-1 to support cancer cell fitness [7]. One type of 
extracellular membrane vesicles that receive increased attention nowadays are exosomes, i.e., 
nanomaps or small membrane vesicles which contain numerous proteins, lipids and even nucleic acids, 
and can travel to distant tissues to influence multiple aspects of cell behavior, including metastatic 
niche preparation [8]. Rab GTPases recruit specific effector proteins and control intracellular vesicle 
transport, including plasma membrane delivery and fusion of a number of different secretory vesicle 
types [9]. The Rab27 family of small GTPases is one important regulator of exosome release [10] and 
is critically involved in breast cancer progression [11–13]. Experimental data from our group and 
others are reviewed with a focus on the secretory Rab27 family of small GTPases and their 
implications in cancer progression. 
2. Rab27 GTPases Guide Vesicle Exocytosis 
Exocytosis involves vesicle transport through the cytoskeleton, the tethering and docking of 
vesicles at exocytic active plasma membrane sites, followed by membrane fusion between the vesicle 
and the plasma membrane. This process results in the secretion of vesicle contents into the 
extracellular environment. One group of proteins central in defining these exocytic events is the family 
of small Rab27 GTPases consisting of two members, Rab27A and Rab27B [14]. Posttranslational 
prenylation of carboxy-terminal cysteine residues allows these Rabs to reversibly localize to vesicle 
membranes. The switch between GTP- and GDP-bound forms (promoted by specific guanine 
nucleotide exchange factors and GTPase-activating proteins, respectively) is crucial for the function of 
small GTPases [9]. In their GTP-bound form, Rab27 proteins bind effector proteins that act during 
vesicle formation, movement, tethering, and fusion, with each pathway having its own unique set of 
effectors [15]. Eleven Rab27-specific effectors have been identified during vesicle movement [16]. 
The spatiotemporal recruitment of these effectors is the principal way by which Rab27 GTPases 
control the efficiency and the specificity of exocytosis of different vesicle types in a cell type-specific 
manner [15]. Rab27 GTPases are widely expressed, whereas the expression of their effectors is 
suggested to be much more restricted, opening a potential window of opportunity for selective 
targeting [17,18]. 
Rab27 family members bind to the surface of distinct vesicle types including lysosome-related 
organelles such as melanosomes in melanocytes and lytic granules in cytotoxic T lymphocytes, 
secretory granules in mast cells and zymogen granules in pancreatic cells [8]. Recently, Rab27 
GTPases have been identified on the cytoplasmic side of the lipid bilayer of multivesicular endosomes 
(MVEs) in HeLa cells [10]. MVEs are complex intracellular organelles that are formed by the 
invagination of the limiting membrane of an endosomal vesicle such that many small intra-endosomal 
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vesicles are formed. Recruitment to the cell periphery and fusion of these MVEs with the plasma 
membrane results in the release of the internal vesicles, termed exosomes [8]. In HeLa cells, 
spontaneous secretion of exosomes is strongly decreased when expression of Rab27 GTPases is 
reduced by short hairpin RNA targeting. In addition, mouse dendritic cells deficient in both Rab27A 
and Rab27B secrete half the number of exosomes compared to their wild type counterparts [10]. 
Inhibitory RNA targeting of Rab27 GTPases in human MDA MB-231 and mouse 4T1 breast cancer 
cells resulted in decreased exosome numbers in culture media [13,19]. This indicates that Rab27 
GTPases are general regulators of MVE transport to the plasma membrane. Vesicle localization studies 
in HeLa cells using confocal microscopy demonstrated that Rab27B mediates the transfer of MVEs 
from microtubules to the actin-rich cortex and their retention at the cell periphery, whereas Rab27A is 
required for the docking to the plasma membrane [10]. Rab27A depletion decreases exosome release 
as well as the secretion of exosome-independent proteins [13]. Immuno-electron microscopy of MCF-7 
breast cancer cells demonstrates that Rab27B is localized on the membrane surface of MVE, but also 
smaller secretory granule-like structures (Figure 1), which suggests that in cancer cells Rab27 small 
GTPases are not restricted to the regulation of MVE secretion, but also other secretory vesicle types. 
Figure 1. Immuno-electron microscopy of MCF-7 breast cancer cells expressing the  
fusion protein GFP-Rab27B. Electron micrographs of ultrathin cryosections of MCF-7  
GFP-Rab27B cells grown on plastic substrate. Rab27B vesicles were immunogold-labeled 
with anti-GFP antibodies (10 nm gold). Left panel: multivesicular endosome (arrowhead: 
Rab27B localization on the membrane surface of a multivesicular endosome; scale bar:  
500 nm). Right panel: secretory granule-like vesicle (white arrow: Rab27B localization on 
the membrane surface of a secretory vesicle; black arrow: point of exocytosis in the 
extracellular environment; scale bar: 100 nm). 
 
3. Rab27 GTPases Drive Invasive Growth and Metastasis 
Rab27 GTPase-mediated vesicle exocytosis is an attractive upstream regulator candidate of invasive 
growth and metastasis, because vesicles can contain entire sets of pro-invasive factors, including 
proteins, mRNAs and miRNAs [20]. Fusion of these vesicles with the plasma membrane results in the 
release of single molecules and/or exosomes with the ability to modulate and determine tumor cell 
behavior in the local tumor ecosystem and at distant sites. A role of exosomes in distant cell-to-cell 
communication was revealed by delivery of exosome-packaged biological active mRNA and miRNA 
from a donor cell to a recipient cell, influencing the latter’s RNA expression, proteome and functions [21]. 
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Work from our group demonstrated that Rab27B promotes invasive growth and metastasis of 
estrogen receptor (ER)-positive breast cancer cells [11]. Breast cancer cells in which Rab27B was 
overexpressed formed cellular extensions and a spread morphology and had a significant increased 
ability to invade Matrigel and native type I collagen substrates. In addition, Rab27B enhanced 
proliferation under limiting serum concentrations. Rab27B stimulated metabolic reprogramming from 
oxidative phosphorylation towards aerobic glycolysis in ER-positive breast cancer cells which was 
accompanied by acidification of the tumor environment [22]. In orthotopic xenograft models Rab27B 
promoted invasive tumor growth as evidenced by increased tumor volume and weight, and massive 
infiltration of the breast cancer cells into the abdominal skeletal muscles. Anchorage-independent 
metastatic cancer cells were present both as single cells or aggregates in the peritoneal cavity [6]. Mass 
spectrometric identification of proteins residing in intracellular Rab27B vesicles revealed different 
exosome markers including the tetraspanins CD9, CD63 and CD81, and the heat shock proteins 
HSP70 and HSP90α (Table 1) [11]. 
Table 1. Mass spectrometric identification of exosome markers in purified intracellular 
Rab27B vesicle fractions.  
Protein identity Matched peptides (#) Sequence coverage (%) 
Tetraspanins   
CD9 3 29.6 
CD63 1 14.2 
CD81 3 21.5 
Heat shock proteins   
HSP70 21 44.3 
HSP90 alpha 13 32.9 
Rab27B overexpression in breast cancer cells resulted in a four-fold increase in the release of 
HSP90α. HSP90α is a molecular chaperone with intracellular and extracellular (amongst which 
exosomal and non-exosomal associated) functions. Extracellular HSP90α can be present as a soluble 
protein or exosome-surface bound protein. The chaperone can be secreted by non-conventional 
exocytosis which involves a C-terminal EEVD motif that interacts with proteins containing 
tetratricopeptide repeat domains and phosphorylation of residue Thr-90 [23]. Flow cytometry analysis 
located HSP90α at the membrane surface of exosomes [24]. Also, acidic extracellular pH has been 
identified as a stimulus of vesicle rupture resulting in the subsequent release of the content [25]. This 
could further contribute to the presence of free HSP90α in the extracellular environment. One reported 
client protein of extracellular HSP90α is MMP-2, a matrix metalloprotease that requires chaperoning 
for its activity [26]. A complex of co-chaperones (HSP70, Hop, HSP40, and p23) is present outside of 
breast cancer cells and co-immunoprecipitates with HSP90α in vitro and in breast cancer conditioned 
media [27]. These co-chaperones also increase the association of HSP90α and MMP-2 and enhance 
HSP90α-mediated activation of MMP-2. These findings support a model in which MMP-2 activation 
by an extracellular co-chaperone complex mediated by HSP90α increases breast cancer cell migration 
and invasion. Probably, the synergistic effect of this extracellular chaperone in the primary tumor  
and exosomes in the metastatic sites is fundamental for the observed functional effects, i.e., invasive 
growth and hemorrhagic ascites, in our xenograft models. Future research aims to unravel the 
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substantial contribution of different Rab27B-steered secretory pathways to the development of an 
extracellular signaling network for cancer progression. One approach involves the complete 
determination of exosome-enriched fractions and exosome-depleted conditioned media of control 
versus Rab27B overexpressing breast cancer cells. Furthermore, in three different ER-positive breast 
cancer models we demonstrated that Rab27A was not able to induce proliferation and invasion in 
collagen type I matrices. Since Rab27A and Rab27B share 70% homology and have the potential  
to interact with a same set of effector proteins this raises an important cell biological question for  
further investigation. 
Rab27A was identified as a driver gene that provides growth advantage during melanoma 
progression [28]. This study made use of a computational framework that integrates chromosomal 
copy number and gene expression to detect driver genes located in regions that are amplified or deleted 
in tumors. Also, Rab27A inhibition in melanoma cell lines reduced primary tumor growth and 
development of lung metastasis in xenograft mouse models [29]. This effect was due to a combination 
of impaired secretion of pro-angiogenic factors and decreased secretion of exosomes that educate  
and recruit bone marrow derived cells to establish a pre-metastatic niche. Combined Rab27A 
dependent-release of MMP-9 and exosomes further contributes to the mobilization of a pro-tumoral 
neutrophil population and supports growth of a mouse mammary tumor and its metastasis in lung [13]. 
In bladder cancer aberrant expression of not only several Rabs, but also Rab effectors, GAPs en 
GEFs was illustrated [30]. Indeed, we recently identified a role for vacuolar H+ (V)-ATPase proton 
pump in Rab27B-dependent exocytosis and demonstrated that Rab27B expression stimulated V-ATPase 
expression suggesting that increased secretory GTPase activity induces expression of components 
necessary to support and steer GTPase regulated vesicle transport [31]. Pharmacological targeting of 
V-ATPase activity by nanomolar concentrations of the macrolide antibiotic bafilomycin A1 resulted in a 
four-fold decreased release of HSP90α in the conditioned medium by breast cancer cells. In agreement, 
by using two different genetic approaches, the membrane-bound V0 sector of V-ATPase has been 
proposed to regulate MVE secretion at the apical plasma membrane in a Caenorhabditis elegans 
model [32]. Our results point to a similar regulatory mechanism in mammalian cells. 
4. Clinical Assessment of Experimentally Validated Pro-Invasive Rab27 GTPases 
Breast cancer heterogeneity is classified into molecular and histopathologic subtypes based 
predominantly on the expression of hormone and growth factor receptors—namely ER, progesterone 
receptor (PR), and HER2. Patients with a triple-negative breast tumor (i.e., ER−/PR−/HER2−) are at the 
greatest risk of early recurrence. ER-positive breast tumors are the most prevalent. These tumors are 
often differentiated and associated with good prognosis, yet a significant number of patients 
experience disease relapse even 10 to 15 years after their initial diagnosis and cancer management [33]. 
Today’s tumor classification has some correlation with patient outcome, however it is difficult to 
accurately predict which patients will relapse. Therefore, we need to find more accurate, sensitive and 
easy accessible predictors of metastatic disease [12]. 
The observation that Rab27B is a key factor for increased invasiveness, tumor size, and metastasis 
of various ER-positive breast cancer cell lines in vitro and in vivo suggests that this small Rab GTPase 
provides an important marker in the signature of ER-positive breast cancers with poor prognosis [12]. 
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Fluorescence in situ hybridization on primary human breast cancer samples detected no amplification 
of the Rab27B gene [11]. But quantitative real-time PCR revealed a 10-fold increase in Rab27B 
mRNA expression in breast tumor tissue (n = 20) compared with normal tissue (n = 5) suggesting a 
higher Rab27B promoter activity or higher posttranscriptional stabilization of Rab27B mRNA. In 
addition, Rab27B mRNA levels were significantly higher in ER-positive primary breast cancer with 
positive nodal status. Rab27A mRNA levels did not significantly differ. Primary breast cancer 
specimens (n = 59) were analyzed by immunohistochemistry using an anti-Rab27B specific polyclonal 
antibody. In ER-positive breast cancer a significant correlation was found among high Rab27B 
expression, nodal status and tumor grade [11]. Rab27B is a well-defined biological marker with the 
high potential to improve ER-positive breast cancer subclassification. Independently, Rab27B 
expression analysis on a cohort of 221 primary breast cancer samples confirmed increased Rab27B 
expression in poor-prognosis breast cancer and identified Rab27B as an independent risk factor for 
survival [34]. Immunohistochemical assessment of Rab27 GTPases in 148 primary hepatocellular 
carcinoma samples demonstrated that presence of Rab27A or Rab27B significantly associated with 
reduced overall survival [35]. The current correlations between Rab27 GTPases and cancer involve the 
upregulation of mRNA and/or protein. Although loss-of-function mutations in the Rab27A gene are 
well-described and known to cause Griscelli type 2 syndrome, it is unclear whether mutations in 
Rab27 genes exist and play a role in cancer biology. Regulation of Rab expression by miRNAs has 
been reported and miRNA124a has been identified as a negative regulator of Rab27A expression [36]. 
In future long-term vision, a prognosis marker may serve as a therapeutic target; widely used 
examples are anti-hormone therapy based on ER positivity and Trastuzumab treatment based on HER2 
positivity. A similar approach is feasible for Rab27 GTPases using effector specific antagonists  
to block exosome release with the aim to control metastasis. Two potential candidates are  
the Rab27-specific effector proteins slp4 and slac2b that are involved in the regulation of MVE  
transport [10]. V-ATPase expression and activity controls Rab27B-induced collagen type I invasion, 
cell cycle progression and invasive growth [31]. Poor prognosis ER-positive primary breast tumors 
expressing high levels of Rab27B also expressed multiple V-ATPase subunits and showed a strong 
cytoplasmic and peripheral V-ATPase expression. Clinically, proton pump inhibitors (PPIs), such as 
esomeprazole, have been largely and successfully used for the treatment of peptic ulcer diseases. PPIs 
target (H1/K1)-ATPases localized within the intracellular secretory lumen of gastric parietal cells. 
Most importantly, PPIs also inhibit the activity of V-ATPases, and thus are potential candidates to 
block Rab27B-mediated exosome release. 
Exosomes are released into the interstitial fluid and may accumulate into biofluids like blood, and 
urine, and are currently emerging as potential non-invasive biomarkers for cancer staging. Multicenter 
studies for biomarker validation would require standardized exosome preparations from these biofluids 
to minimize variability generated by sample collections and isolation techniques. Pre-analytical steps 
such as agitation during transportation, time delay to the first centrifugation step and the centrifugation 
protocol are potential sources of variability [37]. Thus, identification and quantitative characterization 
of nanometer-sized exosomes remains challenging. Direct measurements in the biofluid would be of 
benefit to avoid manipulation artefacts. Furthermore, to prevent sample contamination and enable high 
throughput analysis, these measurements are preferentially performed in inexpensive disposable 
sample holders. One promising approach combines on-chip microfiltration and miniaturized nuclear 
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magnetic resonance to enable quantitative detection of exosomes labeled with target-specific magnetic 
nanoparticles [38]. We developed a low-cost disposable microfluidic chip with integrated light sheet 
illumination for high-throughput exosome staging in cancer patients [39]. Light sheet illumination 
enables on-chip detection of exosomes that are fluorescently labeled directly in biofluids without  
pre-processing steps.  
5. Conclusions  
Despite many advances, cure rates for advanced cancer remain low. There is an imperative need to 
identify new targets to control metastatic cancer. We consider cancer as an endocrine organ that 
releases exosomes affecting the host at a systemic level and particularly at the preparation of metastatic 
niches. The traits that a cancer acquires to successfully grow and metastasize to distant sites are at least 
partly regulated by aberrant vesicular transport and its effectors are major contributors to this 
regulatory process. Future experiments are expected to define selective and specific functions for Rab27 
effectors in exosome release, as well as establish potential opportunities for immunohistochemical and 
blood-based prognostic biomarkers and therapeutic intervention for the treatment of cancer. 
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